U.S. Markets open in 7 hrs 13 mins
  • What to watch in the markets: Tuesday, August 22

    Here's a look ahead at what will be making headlines on Tuesday, August 22

    Read More »
  • Your Credit Score Could Make or Break Your Love Life
    Business
    Bloomberg21 hours ago

    Your Credit Score Could Make or Break Your Love Life

    One study, released two years ago, looked at consumer credit data over 15 years and found that the higher the year-end credit score, the likelier the person was to form a romantic relationship over the next year. Now comes a survey from Discover Financial Services and Match Media Group, parent of Tinder and other dating sites, that shows just how appealing a good credit score can be. Financial responsibility was ranked as a very or extremely important quality in a potential mate by 69 percent of the 2,000 online daters surveyed.

  • McDonald's to shut 169 outlets in India amid dispute with local partner
    Finance
    Reuters14 hours ago

    McDonald's to shut 169 outlets in India amid dispute with local partner

    Fast food chain McDonald's said on Monday it planned to shut all 169 of its restaurants in India's northern and eastern regions, escalating a dispute with its local partner and potentially putting thousands of workers out of jobs. The U.S. company said it was "compelled" to take the action because its partner Connaught Plaza Restaurants Pvt Ltd (CPRL) had breached the terms of their franchise agreements. Vikram Bakshi, managing director of CPRL, told Reuters the decision came as a "big shock" and the company was studying all its legal options.

  • Gilead: Where’s the Urgency?
    Business
    barrons.com12 hours ago

    Gilead: Where’s the Urgency?

    Gilead Sciences (GILD) has gained 13% during the past three months as investors have started to bet that the beaten-down biotech stock has finally found a bottom. But do you need to buy Gilead now? That seems to be the key debate around Gilead, say Jefferies analyst Michael Yee and team, who ask "whether there is urgency to buy it now." They explain: ...relative increasing interest as biotech has turned more favorable since June and relative growing sense GILD has seen the bottom. Key investor debate is whether there is urgency to have to buy it now vs it's still a little early and perhaps wait for 2018 with more HCV clarity after AbbVie ( ABBV) launches/formulary access and mkt share is more